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Abstract 
 
Objective: To assess the characteristics and core statistical methodology specific to network 
meta-analyses (NMAs) in clinical research articles.  
Study Design and Setting: We searched Medline, Embase and the Cochrane Database of 
Systematic Reviews from inception until April 14, 2015 for NMAs of randomized controlled 
trials (RCTs) including at least four different interventions. Two reviewers independently 
screened potential studies, while data abstraction was performed by a single reviewer and 
verified by a second. 
Results: A total of 456 NMAs, which included a median (interquartile range) of 21 (13 to 40) 
studies and 7 (5 to 9) treatment nodes were assessed. A total of 125 NMAs (27%) were star 
networks; this proportion declined from 100% in 2005 to 19% in 2015 (p=0.01 by test of 
trend). An increasing number of NMAs discussed transitivity or inconsistency (0% in 2005, 
86% in 2015, p<0.01) and 150 (45 %) and used appropriate methods to test for inconsistency 
(14% in 2006, 74% in 2015, p<0.01). Heterogeneity was explored in 256 NMAs (56%), with 
no change over time (p=0.10). All pairwise effects were reported in 234 NMAs (51%), with 
some increase over time (p=0.02). The hierarchy of treatments was presented in 195 NMAs 
(43%), the probability of being best was most commonly reported (137 NMAs, 70%) but use 
of SUCRA (surface under the cumulative ranking curves) increased steeply (0% in 2005, 33% 
in 2015, p<0.01). 
Conclusion: Many NMAs published in the medical literature have significant limitations in 
both the conduct and reporting of the statistical analysis and numerical results. The situation 
has however improved in recent years, in particular with respect to the evaluation of the 
underlying assumptions, but considerable room for further improvements remains. 
 
278 words 
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What is new? 
 
 
Key findings 
Although the amount of evidence (the number of treatments and studies) included in 
published NMAs remains stable, the undertaking and reporting of statistical methods have 
significantly improved over the years. The assumptions underlying NMA are increasingly 
discussed and evaluated using appropriate methods. Less than 10% of NMAs published in 
2014 and 2015 failed to evaluate the assumptions of the joint synthesis. 
 
 
What this adds to what is known 
This meta-epidemiological study presents the largest collection of published NMAs over 
the past 16 years. It provides an overview of the structural characteristics and statistical 
methodology of 456 published networks of interventions. It shows that the statistical 
methods in NMA have considerably improved in all aspects and some, such as the use of 
appropriate methods to evaluate the plausibility of the assumptions, are now routinely 
performed. We conclude that the increasingly populous community of NMA 
methodologists is quickly advancing through the learning curve of statistical methods 
employed in NMA. 
 
 
What is the implication, what should change now 
The updated description of the structural characteristics of the published NMAs can be 
used to inform pragmatic simulations studies and the development of methods that are 
relevant to the type of networks typically found in the medical literature. 
Future tutorials and training should be focused on improving the methodology and 
reporting on items that, although they have improved, their prevalence remains low, such 
as the formal exploration of heterogeneity and inconsistency and the presentation of all 
pairwise treatment effects. 
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1 Introduction 
Network meta-analysis (NMA) is becoming increasingly popular for evidence synthesis [1–4] 
with enthusiasts considering NMA as the ‘new norm’ for comparative effectiveness research 
[5]. However, empirical studies exploring the characteristics of published NMAs of 
interventions have raised the need for improving the quality of the application of NMA 
methods [1,2,6–9]. Concerns about inappropriate applications of NMA methods and 
inadequate and non-transparent reporting of methods and results have been  identified as 
major issues [10–12]. For instance, Nikolakopoulou et al. found that 68% of the NMAs 
published by the end of 2012 used either inappropriate or unspecified methods to assess 
inconsistency, while Bafeta et al. concluded that reporting guidelines are necessary to reduce 
heterogeneity in presentation of NMA results [1,6].  
The importance of empirical evidence in a novel, rapidly evolving methodological field is 
illustrated by the role such studies played in shaping the methodology for conventional 
pairwise meta-analysis. The assessment of risk of bias in the included studies [13–15], the 
magnitude and determinants of heterogeneity [16–18], the relative advantages of different 
methods to evaluate publication bias and small-study effects, [19–21] and the importance of a  
comprehensive search for relevant studies [22] are examples of meta-epidemiological studies 
that have guided the choice of optimal methods. We are aware of only three such meta-
epidemiological studies in NMA: Song et al. evaluated the prevalence of inconsistency in 
networks with three treatments [23,24], Veroniki et al. studied the prevalence of inconsistency 
in complex NMAs that included at least four treatments using two alternative methods [25] 
while Chaimani et al. have provided empirical evidence about the impact of risk of bias and 
small study effects [26].  
In recent years, the methodology of NMA has been further refined and many tutorials and 
guidance papers have been published [12,27–31]. Efthimiou et al., in a recent review of 
methodological articles published until March 2014, [32] found a steep increase after 2011 in 
the number of relevant publications. In 2012 and 2013, 83 methodological articles were 
published compared to 58 articles between 2005-2011. For example, until recently most 
networks were fitted within a Bayesian framework as hierarchical models [1], but new NMA 
methods include publications by White et al. suggesting NMAs can be viewed as a specific 
case of multivariate meta-regression, and by Higgins et al. presenting a new test for 
inconsistency [33,34]. Their work enables researchers to fit models using frequentist 
software. Stata routines were made available by White et al. and Chaimani et al. that 
simplified NMA implementation by non-statisticians [35–39].  
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In this paper, we aim to describe how methodologies specific to NMA and reporting quality 
of results has evolved over time, monitor the rate of adoption for the new methodological 
developments and provide an updated overview of the characteristics of published networks. 
2 Methods 
2.1 Inclusion criteria  
Networks of randomized controlled trials (RCTs) were eligible if they included at least four 
different interventions (defined as different drugs or other medical treatments, or different 
schedules, doses or formulations of the same treatment) including placebo, no treatment, 
waiting list or other control interventions. We excluded networks that included observational 
or diagnostic test accuracy studies, NMAs in which the number of trials was smaller than the 
number of interventions and articles that performed naive indirect comparisons by pooling 
data across study arms.  
2.2 Literature search 
An expert librarian compiled the literature search, which was peer-reviewed by a second 
librarian using the Peer Review of Electronic Search Strategies (PRESS) checklist [40]. 
Subsequently, Medline, Embase and the Cochrane Database of Systematic Reviews were 
searched from inception until April 14, 2015.  The full literature search strategy is provided in 
the Appendix. There were no language restrictions on our search. 
2.3 Screening 
After a pilot-test of the eligibility criteria, pairs of reviewers (MG, AC, MP, AAV, PR, AV, 
SS) independently screened the titles and abstracts from the literature search. Potentially 
relevant full-text papers were screened in the same manner. Conflicts were resolved by a third 
reviewer (AAV, AN, AC, GS, PR) to increase consistency. 
2.4 Data extraction and data items 
One reviewer (MP, AN, AC, AAV, MG, PR, AV, SS or WZ) abstracted data from the 
included studies and then data was checked by another reviewer. Data items included general 
publication characteristics: e.g.., year of publication, country of corresponding author and 
journal of publication. We recorded whether the primary outcome measured efficacy or safety 
and classified outcomes as dichotomous, continuous, time-to-event or rate. For networks that 
indicated none or more than one outcome as primary, we used discussion to reach consensus 
for a final decision. We extracted the total number of compared interventions (termed nodes 
of the network henceforth), the reference intervention when reported (placebo, usual care, no 
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treatment, or active treatment). We categorized each network according to the type of 
treatment comparisons as pharmacological versus placebo, pharmacological versus 
pharmacological or non-pharmacological versus any treatment (for details see Turner et al. 
[41] and Nikolakopoulou et al. [1]). When the reference treatment was not explicitly defined, 
one of the following was selected as the reference treatment node: placebo, usual care, or no 
treatment. We also categorised the shape of network according to the presence or absence of 
at least one closed loop.  
We only examined methodological characteristics that are specific to NMA methodology, 
with an emphasis on statistical analysis and reporting. We recorded whether and how the 
authors evaluated the plausibility of transitivity (the comparability of the distribution of effect 
modifiers across treatment comparisons) prior to the data synthesis [27]. For networks 
including at least one closed loop, we also recorded the use of any statistical method to 
evaluate consistency (e.g. statistical methods such as those described in Donegan et al. 
(2013)) [42]. We categorized the method used to derive indirect and/or network estimates 
(e.g. a Bayesian hierarchical model, a multivariate meta-analysis approach), effect measure 
employed to undertake the analysis (such as odds ratio or mean difference) and whether 
fixed-effects model, random-effects model or both computational models were used. We also 
assessed any secondary analyses such as subgroup, network meta-regression, or sensitivity 
analyses that the authors performed to investigate potential sources of heterogeneity or 
inconsistency. We examined whether authors assessed small-study effects, whether they 
considered the potential for publication bias and the methods they applied to evaluate their 
impact on the results. We recorded whether all possible relative effects were presented (in the 
main text or as supplementary material) or only a subset of them. We also examined whether 
the authors presented the estimated hierarchy of the included interventions and which 
measure was used for this purpose (such as probability of being the best or surface under the 
cumulative ranking (SUCRA) curve [11,43,44]).  
2.5 Statistical analysis 
We performed a descriptive analysis for all the characteristics we extracted from the eligible 
networks of interventions. For characteristics that have been previously identified as needing 
improvement [1,2,45] –  such as the adoption of appropriate methods to evaluate consistency, 
the uptake of frequentist methods for NMA, and the transparency of reporting –  we evaluated 
whether there was a change in frequency over time.  We formally tested the trend using a X2 
test for trends in proportions for dichotomous characteristics and the Cox-Stuart test for trends 
in continuous characteristics [46]. We also investigated any associations between methods 
employed and the complexity of the evidence-base such as the number of nodes and the 
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presence of closed loops. All analyses were performed in R software [47] using the trend 
library [48].  
3 Results 
The search identified 3727 citations and after screening the titles and abstracts, 877 
potentially relevant full text articles were reviewed. In total, 456 NMAs met all inclusion 
criteria. The full selection process for the included networks is presented in Figure 1.  
 
Figure 1 Flow chart of the selection process for the included networks. 
 
Table 1 presents a description of the sample. The median number of studies per network was 
21 (interquartile range (IQR) 13 to 40) and the median number of treatments was 7 with an 
IQR of 5 to 9. The majority of NMAs included at least one closed loop (331, 73%) while 
nearly a quarter of the networks (125 NMAs, 27%) did not contain a closed loop of evidence 
(called star-shaped networks). The majority of the included NMAs had a beneficial primary 
outcome (260 NMAs, 57%) that was commonly measured using a dichotomous outcome (267 
NMAs, 59%). The primary outcome was measured using continuous data in 135 NMAs 
(30%).  Two-thirds of the networks compared pharmacological treatments and included 
placebo (299 NMAs, 66%) while one in five compared only pharmacological interventions 
(88 NMAs, 19%). A small number of networks had a mixture of pharmacological, non-
pharmacological and control treatments (69 NMAs, 15%).  
 
Table 1 Characteristics of 456 NMAs published until 2015. IQR: Interquartile range. 
 
Most of the included articles were published in general medicine journals (183 NMAs, 40%), 
the most common was the British Medical Journal (28 NMAs, 6%) followed by Current 
Medical Research & Opinion (24 NMAs, 5%). Corresponding authors of 234 NMAs (51%) 
had an affiliation in a European country (92 NMAs, 20% for United Kingdom) and 140 
NMAs (31%) had an affiliation in the United States.  
3.1 Time trends in the characteristics of NMAs 
Between 1999 and 2004 only 6 NMAs were published (1 in 1999, 2 in 2000, 1 in 2003 and 2 
in 2004).  The number of NMAs published per year after 2004 is presented in Table 2. It is 
evident that the number of published studies applying NMA methods to clinical research 
questions has been increasing significantly over the last two decades (p=0.04).  
Overall, the networks of published NMAs do not seem to include more studies (p=0.08, data 
not shown) or to compare more treatments in recent years (p=0.72, data not shown). 
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However, the proportion of star-shaped networks has decreased with time while the number 
of networks with at least one closed loop has increased (p=0.01, Table 2).  
 
Table 2 Networks published between 2005 and 2015 (until 15 April) and their 
characteristics. The entries in the table show number of networks and respective 
percentages. P-values are from a trend test. *There are 6 networks published before 2005 and 
are included in the total NMA group. ** In the test for trend for the total number of published 
NMAs we excluded the year 2015 as it is not complete. ***Here the denominator is the 
number of articles with at least one closed loop (number of NMAs published minus the star-
shaped NMA).  
3.1.1 Evaluation of clinical and statistical assumptions 
In three quarters of the included articles (353 NMAs, 77%) we could not identify any 
statement suggesting that the transitivity (or similarity) assumption was considered or 
evaluated (Table 2). However, this has improved considerably over time, with 77% of the 
networks published in 2015 discussing transitivity (p<0.01). In five networks, the authors 
expressed concerns about the presence of potential non-transitivity and its impact on the 
results. Among the remaining 100 networks that did report how transitivity was evaluated, the 
majority compared the study characteristics (76 networks) (Appendix Table 1). One in five of 
the published networks (22%) reported that the transitivity assumption is likely to hold; the 
rate of articles reporting this information has increased over time (p<0.01).  
Statistical evaluation of consistency was possible for 331 networks that included at least one 
closed loop. Almost one third of these NMAs (94 NMAs, 28%) did not report any method 
used for the statistical evaluation of consistency. Nearly half of the networks (150 NMAs, 
45%) used appropriate statistical methods to evaluate consistency; their uptake has increased 
over time (p<0.01, Table 2).  
The exact method used for assessing inconsistency in each network is detailed in Appendix 
Table 2. The loop-specific approach [49] was the most commonly employed method (59 
NMAs, 18%), followed by the node-splitting approach [50] (39 NMAs, 12%). The design-by-
treatment interaction model [34] that was introduced in 2012 was used in very few networks 
(5 NMAs, 2%). The proportion of NMAs that considered transitivity or consistency using any 
method increased significantly over time (p<0.01, Table 2); 86% of the articles published in 
2015 reported mentioned at least one of the two terms.  
Appendix Table 1 Reporting and evaluation of transitivity. Number of articles and 
percentages. 
Appendix Table 2 Statistical methods used to evaluate the consistency assumption in 331 
NMAs with at least one closed loop. 
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In total we found 76 networks that did not evaluate either transitivity or inconsistency (23% 
for the networks where assessment of both was possible); the percentage has dropped from 
35% in 2010 to 19% in 2012 and to 8% in 2014/2015 (p<0.01).   
3.1.2 Statistical synthesis of data 
We found that the odds ratio (177 NMAs, 39%) and the mean difference (89 NMAs, 20%) 
were the most frequently used effect sizes for networks with dichotomous and continuous 
data respectively. It was not always clear whether the random or fixed effects model was used 
although reporting improved with time (p=0.01, Table 2). The majority of the included 
networks (230 NMAs, 50%) performed the analysis using a random-effects model.  Of the 
170 networks (37%) that used the fixed-effect model, the majority (141 NMAs, 83%) also 
applied the random-effects approach either as a sensitivity analysis or with the aim to choose 
between the two models.  
 The percentage of articles reporting the statistical method used to fit NMA has increased over 
time (p<0.01, Table 2) and only a small proportion of networks (24 NMAs, 5%) did not report 
the NMA method used. The Bayesian hierarchical model remains the most popular approach 
for NMA (302 NMAs, 64%). Only 80 (18%) networks which included at least one multi-arm 
study employed methods to derive the treatment effect that ignored correlations (e.g. adjusted 
indirect comparison meta-analysis or Bucher method). NMAs using multivariate meta-
analysis or multivariate meta-regression was encountered in only 5 publications while the 
graph-theoretical method for NMA was employed in one network. 
Figure 2 Method used to synthesize the data in relation to the shape of the network. If a 
network applied more than one method, it is included in all relevant categories.  
 
Figure 2 illustrates that review authors tend to employ a Bayesian hierarchical approach and 
meta-regression more often in the presence of closed loops.  
Approximately half of the networks (256 NMAs, 56%) investigated potential sources of 
heterogeneity or inconsistency via the use of subgroup, meta-regression or sensitivity 
analysis. This remained unchanged over time (p=0.10). Small-study effects and publication 
bias were assessed in 143 (31%) networks. Funnel plots (116 NMAs, 81%) and regression 
tests (82 NMAs, 57%) were the most prevalent methods for the assessment of publication bias 
and 7 NMAs (5%) applied trim and fill method (Appendix Table 3). These methods were 
primarily applied to the direct comparisons and only a handful of networks (6 NMAs, 4%) 
considered the extensions for the aforementioned approaches into the context of NMA, such 
as the comparison adjusted funnel plot and extended selection models [36,51–53].  
Appendix Table 3 Methods employed to assess small-study effects and/or publication 
bias in 143 NMAs. 
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3.1.3 Presentation of results 
The percentage of NMAs that report outcome data for the primary outcome decreased with 
time (p=0.03). Half of the included reviews (234 NMAs, 51%) presented all possible relative 
treatment effects; the other half present only a selective set of comparisons of interest. Newer 
articles tend to be more inclusive and present all pairwise effects (p=0.02, Table 2).  One 
network (0.2%) did not report any relative treatment effect. The relative hierarchy of the 
treatments was presented in 43% (195 NMAs) of networks. Probability of being the best was 
the most popular ranking measure employed to derive a treatment hierarchy (166 NMAs, 
85%) followed by SUCRA (39 NMAs, 20%) (Appendix Figure 1). While the frequency of 
exclusive use of the ‘probability of being the best’ has not changed significantly over time 
(p=0.86, Table 2), the use of SUCRAs has  increased sharply (p<0.01, Table 2).  
 
Appendix Figure 1 Ranking measures used in the included networks per year (1999-
2015).  
4 Discussion  
 
We identified 456 NMAs that were published between 1999 and 2015 by searching three 
bibliographic databases and assessed the characteristics of their statistical analysis and 
reporting of results. We found that many NMAs published during this time period have 
significant methodological limitations, but that the application of some methodological 
elements improved in recent years. For example an increasing number of published NMAs 
addressed transitivity or inconsistency, by 2015 about three quarters of analyses used 
appropriate methods to test for inconsistency. The quality and transparency of reporting also 
increased: in recent years around 90% of articles clearly reported whether a random-effects or 
fixed-effect model was used, and in 2015 all reports included a description of the statistical 
methods used. However, important deficiencies in the application of NMA methods remain: 
discussion of the transitivity assumption was rare and only about half of the articles reported 
the results of all pairwise comparisons with no increase in recent years. It should be noted that 
the Bayesian hierarchical model remained the most popular approach for NMA during the 
study period: only five articles reported the use of frequentist multivariate meta-analysis or 
meta-regression.  
Our study has several strengths. Expert librarians conducted a comprehensive literature search 
in multiple bibliographic databases and our study team peer reviewed the literature search, 
screened articles in duplicate using standardized tools, and extracted and verified the relevant 
information using standardized forms. Calibration exercises among all reviewers preceded 
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each step of the review. We identified 456 NMAs, which were published over the past 17 
years and although our search may have missed some articles, it is very likely that we 
identified a set of NMAs that accurately reflects current and past practice and methodological 
development. To the best of our knowledge, this is the largest and most up-to-date collection 
of published NMAs compiled to date. It includes nearly three times the data included in 
Bafeta et al. [2], more than twice the data included in Nikolakopoulou et al., [1] and about 
40% more data compared to the collection recently published by Chambers et al. [54]. This is 
also the first study to formally investigate the changes in the methodology and reporting of 
NMAs over time. 
Previous empirical studies have motivated various groups to develop recommendations to 
improve the practice and reporting of NMAs. For example, Hutton et al. developed an 
extension of the PRISMA statement (Preferred Reporting Items for Systematic reviews and 
Meta-analysis) for the reporting of systematic reviews that include NMAs of health care 
interventions  [45]. The National institute of Clinical excellence (NICE) in the UK and the 
International Society For Pharmacoeconomics and Outcomes Research (ISPOR) have also 
developed relevant guidance [31,55].  
We observed an important improvement in the statistical methodology and reporting of 
NMAs over time. The PRISMA statement was published only recently and we do not expect 
it to have had any major impact on the improvements in reporting observed in our study. The 
educational papers published several years ago [12,27,28,56,57] might, however, have had 
some impact. Alternatively, improvements in NMA methods might be due to statisticians and 
clinicians becoming more experienced with NMA techniques. This ‘learning curve’ could be 
accelerated by developments making methods more accessible and more widely available. 
We found that features adding to the complexity of evidence structures, such as closed loops 
and large numbers of studies, were more common in NMAs performed within a Bayesian 
framework. The frequentist approaches to NMA that can cope with large and complex 
networks, such as the routine in Stata that fits the multivariate random-effects meta-analysis 
model [33,39], have not been applied widely but are expected to be increasingly used in the 
next years. Similarly, the design-by-treatment interaction model to test for inconsistency [34] 
that was introduced in 2012 was used in only few networks. This may be explained by the 
fact that the parameterization of this model is complex and until recently no dedicated 
software was available [39]. 
The transitivity assumption is imperative for a valid NMA and also needs to be met when 
informally comparing effects estimates from separate pairwise meta-analyses. In our large 
collection of networks, the vast majority of reports did not mention the transitivity assumption 
and only a handful of NMA reviews assessed it through the comparison of the distribution of 
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effect modifiers. Suggestions of accompanied detailed protocols on which authors should 
base their NMA reviews [12,27] have started to be applied. Among other merits, 
establishment of NMA protocol registration could substantially improve reporting and 
evaluation of transitivity through the a priori description of approaches that will be used to 
assess it. 
 
Almost 10 years ago Sutton and Higgins stated that “time will tell whether this [NMA] is how 
efficacy of treatments will be routinely compared in the future” [58]. The substantial increase 
in published NMAs supports the notion that the rationale, importance, and methodology of 
comparing multiple treatments simultaneously has now become acknowledged among 
researchers,  national and international health-care institutions [56]. It would be useful if the 
database used for this study was to be regularly updated to monitor developments in NMA 
publication and serve as a resource for further empirical research to better define the place of 
NMA in comparative effectiveness research. Several such projects are ongoing or planned: 
the quality of the systematic reviews providing data for each of the 456 networks is currently 
being evaluated, networks are currently being re-analysed to estimate the prevalence of 
statistical inconsistency, updating previous empirical research [25], and a subset of the 
included NMAs is being evaluated with respect to their conclusiveness using sequential 
methods. Additionally, the methodology to compare different doses of the same intervention 
within NMA is not well developed and an ongoing scoping review plans to describe the 
approaches currently available in the published literature. Finally, our database could inform 
simulation studies and scenarios evaluating the performance of various methodological 
approaches so that simulations reflect the most common encountered circumstances, as was 
previously done in Veroniki et al. [61]. 
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Table 1 Characteristics of 456 NMAs published until 2015. IQR: Interquartile range. 
 Median  IQR 
Median number of treatments compared 7 (5, 9) 
Median number of studies included 21 (13, 40) 
 Number of NMAs % 
Number of star-shaped networks 125 (27%) 
Outcome characteristics   
Beneficial outcome 260 (57%) 
Measured as dichotomous 267 (59%) 
Measured as continuous 135 (30%) 
Compare pharmacological treatments and placebo 299 (66%) 
Compare only pharmacological treatments  88 (19%) 
Published in general medicine journals1 183 (40%) 
Published in health services research journals2 56 (12%) 
Published in specialty journals 217 (48%) 
Corresponding author with affiliation in Europe 234  (51%) 
Corresponding author with affiliation in USA 140   (31%) 
 
1 Includes the categories Medicine, General & Internal, Pharmacology & Pharmacy, Multidisciplinary Sciences, Medicine, Research & Experimental, Primary Health Care.  
2 Includes the categories Health Care Sciences & Services, Health Policy & Services 
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Table 2 Networks published between 2005 and 2015 (until 15 April) and their characteristics. The entries in the table show number of networks and respective percentages. P-values are from 
a trend test. *There are 6 networks published before 2005 and are included in the total NMA group. ** In the test for trend for the total number of published NMA we excluded the year 2015 
has it is not complete. ***Here the denominator is the number of articles with at least one closed loop (number of NMAs published minus the star-shaped NMAs). 
Characteristics of NMAs Total 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 p-
value 
Characteristics of the evidence-base 
 
Star Networks 125 6 100% 5 42% 2 22% 6 50% 7 26% 7 23% 14 26% 17 29% 19 20% 32 31% 8 19% 0.01 
Compare pharmacological 
vs pharmacological 88 1 17% 2 17% 2 22% 3 25% 8 30% 3 10% 5 9% 5 8% 23 24% 29 28% 7 16% 0.15 
Compare pharmacological 
vs placebo 299 5 83% 8 67% 6 67% 9 75% 14 52% 22 73% 43 81% 42 71% 62 65% 56 54% 26 60% 0.31 
Compare non-
plarmacological vs any 69 0 0% 2 17% 1 11% 0 0% 5 19% 5 17% 5 9% 12 20% 11 11% 18 17% 10 23% 0.05 
Evaluation of clinical and statistical assumptions 
 
No information or 
discussion on transitivity 353 6 100% 12 100% 7 78% 11 92% 23 85% 26 87% 46 87% 46 78% 67 70% 71 69% 33 77% <0.01 
Reported that transitivity is 
likely to hold 98 0 0% 0 0% 1 11% 1 8% 4 15% 4 13% 7 13% 13 22% 27 28% 30 29% 10 23% <0.01 
Use appropriate methods to 
test for inconsistency*** 150 ΝΑ ΝΑ 1 14% 2 29% 2 33% 6 30% 4 17% 13 33% 16 38% 43 56% 36 51% 26 74% <0.01 
Discuss  transitivity or 
inconsistency (at least one of 
the two) 
285 0 0% 2 17% 3 33% 5 42% 12 44% 17 57% 30 57% 40 68% 66 69% 72 70% 37 86% <0.01 
Statistical synthesis of data 
Clearly reported  whether 
random or fixed effects are 
used 
400 5 83% 10 83% 7 78% 10 83% 20 74% 25 83% 44 83% 53 90% 91 95% 93 90% 38 88% 0.01 
Method for NMA reported 432 4 67% 8 67% 9 100% 11 92% 23 85% 30 100% 51 96% 56 95% 95 99% 99 96% 43 100% <0.01 
Use Bayesian hierarchical 
model to fit NMA 302 1 17% 3 25% 3 33% 4 33% 13 48% 19 63% 35 66% 43 73% 77 80% 71 69% 33 77% <0.01 
Formal exploration of 
heterogeneity 256 2 33% 9 75% 5 56% 6 50% 16 59% 20 67% 36 68% 32 54% 56 58% 51 50% 20 47% 0.1 
Presentation of results 
All pairwise effects are 
presented 234 1 17% 3 25% 2 22% 4 33% 15 56% 17 57% 31 58% 29 49% 54 56% 55 53% 23 53% 0.02 
Available outcome data 308 4 67% 8 67% 8 89% 10 83% 23 85% 24 80% 36 68% 38 64% 55 57% 71 69% 27 63% 0.03 
Use Pbest as the only 
method of ranking 137 1 17% 2 17% 3 33% 1 8% 10 37% 13 43% 16 30% 20 34% 33 34% 32 31% 6 14% 0.86 
Use SUCRA to rank 
treatments 39 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 1 2% 4 7% 10 10% 9 9% 14 33% <0.01 
Number of NMAs published 456* 6 12 9 12 27 30 53 59 96 103 43 0.04** 
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*Two networks reported more than one approach to 
evaluate transitivity, the denominator is the total 
number of networks (456). **Authors stated that they 
assume on the outset that the transitivity assumption is 
likely to hold without justifying this decision. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Appendix Table 1. Reporting and evaluation of transitivity: number of articles and percentages.  
Reported concerns about potential intransitivity 5 (1.1%)  
Nothing relevant reported 353 (77.4 %)  
Transitivity established 100* (21.9 %) 
 
 
 
 
Method to evaluate transitivity among 
those claiming transitivity* 
Compare the distribution of the effect 
modifiers across studies grouped by 
comparison 
  11 (11%) 
Compare the characteristics of the 
included trials 
  76 (76%) 
Use of meta-regression   9 (9%) 
Assumed on the outset** 4 (4%)  
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*13 networks used more than one method to evaluate 
consistency. Here the denominator is the number of 
networks with at least one closed loop (331). 
 
 
 
 
 
 
 
 
 
 
  
Appendix Table 2. Statistical methods used to evaluate the consistency assumption in 331 NMAs 
with at least one closed loop. 
Inconsistency methods Number of networks* 
Appropriate methods  164 (49.5 %) 
A
p
p
r
o
p
r
i
a
t
e
 
 
m
e
t
h
o
d
 
u
s
e
d
*
 
Loop-specific [1] 59 (17.8 %) 
Node-splitting [2] 39 (11.8 %)     
Back-calculation [2]  8 (2.4 %) 
Comparisons of model fit and parsimony (DIC) [3] 21 (6.3%) 
Inconsistency models (Lumley model [4], Lu and Ades 
model [5],  Design-by treatment model [6]) 
33 (10 %) 


 [7] 3 (0.9 %) 
Generalized Cochran Q [8] 1 (0.3%) 
Inappropriate methods  88 (26.5 %) 
I
n
a
p
p
r
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t
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m
e
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Comparison of NMA results with direct meta-analysis 
results 
65 (19.6 %) 
Comparison of the results with previously published 
results 
23 (6.9 %) 
 No method reported 94 (28.3 %) 
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*55 networks applied more than one method. 
Here the denominator is the number of 
networks which assess small-study effects 
and/or publication bias (143). 
  
Appendix Table 3 Methods employed to assess small-study effects and/or publication bias in 143 NMAs.  
Method Number of networks* 
Funnel plots (standard or contour-enhanced [9], [10]) 116 (81.1 %) 
Regression tests (Egger’s [9], Begg’s [11], Harbord’s [12], Peter’s [13]) 82 (57.3 %) 
Trim and Fill method [14] 7 (4.8 %) 
Comparison-adjusted funnel plots [15] 5 (3.4 %) 
Extended selection models in NMA [16]–[18]  1 (0.6 %) 
L' Abbe plot [19] 1 (0.6 %) 
Fail-safe number (Nfs) (Number of studies with zero effect size that would be 
needed to increase the p-value for the meta-analysis to above 0.05 [20])  
2 (1.3 %) 
Tolerance level for future null results (Number of studies averaging null results 
that must be in the file drawers before the overall probability of a Type I error is 
brought to any desired level of significance [20]) 
1 (0.6 %) 
Other (e.g. analyses the publication rates of the included studies;  investigated 
from previous completed reviews; comparison the results with other study) 
4 (2.7 %) 
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Appendix Figure 1 
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